Blue Jet Healthcare Limited — Investor Meet, 03-08-2026: Analysts/Institutional Investor Meet/Con. Call Updates

Blue Jet Healthcare reported Q1 FY27 results. Revenue from operations rose 25% QoQ to ₹293.1 Cr, driven by strong Pharma Intermediates & API sales. EBITDA surged 38% QoQ to ₹98.1 Cr (33% margin), boosted by operating leverage. PAT increased 22% QoQ to ₹78.3 Cr. However, YoY, revenue declined 17% and PAT fell 14% due to lower Pharma Intermediates sales compared to Q1 FY26. Key updates include the Hyderabad R&D center on track for Sept’26, commencement of the Vizag project, and a successful ₹800 Cr QIP for growth. The company is strategically focused on capacity expansion and R&D investment for future growth.